Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About |
---|
The Effect of Oral Magnesium Pidolate on How Often Painful Crises Happens in Patients with Hemoglobin SC Disease
This study is currently recruiting patients.
Sponsored by: | Baylor College of Medicine
Texas Children's Hospital
Children's Hospital Boston
|
---|---|
Information provided by: | Baylor College of Medicine |
Purpose
The purpose of this study is to find out whether treatment with magnesium pidolate will increase the amount of water in the red blood cell and result in fewer painful crises in patients with hemoglobin SC disease while not causing diarrhea.
Condition | Treatment or Intervention | Phase |
---|---|---|
Hemoglobin SC Disease |
Drug: Mg Pidolate |
Phase II |
MedlinePlus related topics: Sickle Cell Anemia
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Safety/Efficacy Study
Official Title: The Effect of Oral Magnesium Pidolate on Incidence of Painful Crises in Patients with Hemoglobin SC Disease
Expected Total Enrollment: 20
Study start: March 2000
Patients will be randomly assigned to study medication (Mg pidolate or placebo) for 24 weeks, followed by a washout period of 8 weeks. After the washout period each patient will receive a further 24 weeks of study medication.
Eligibility
Genders Eligible for Study: Both
Criteria
Inclusion criteria:
This protocol is open to male and female patients of all races with a diagnosis of severe sickle hemoglobinopathy providing they also satisfy the following eligibility criteria:
Exclusion Criteria:
Location and Contact Information
More Information
U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
National Institutes of Health, Department of Health & Human Services | ||||||||||||||
Copyright, Privacy, Accessibility, Freedom of Information Act |